CSL signs rare-disease deal and CSL stock costs EUR 114.58

Published on 10/12/2026 at 09:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL commits USD 355 million and up to USD 1.2 billion in milestones. CSL stock was EUR 114.58 on October 12, 2026, with an October 27 AGM.

Key points in brief

CSL announced an exclusive lixudebart partnership with Alentis on October 5, 2026.
The agreement includes a USD 355 million upfront payment and up to USD 1.2 billion in milestones.
CSL stock was trading at EUR 114.58 at Lang & Schwarz on October 12, 2026.
CSL reported USD 15.8 billion in fiscal 2026 revenue, up 1.50 percent from fiscal 2025.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL (ISIN AU000000CSL8) was trading at EUR 114.58 at Lang & Schwarz on October 12, 2026, at 9:09 a.m. CEST. The company had announced an exclusive rare-disease partnership with Alentis on October 5, committing USD 355 million upfront and up to USD 1.2 billion in commercial milestones.

Deal expands rare-disease pipeline

According to CSL on October 5, 2026, the companies will co-develop and co-promote lixudebart for rare kidney, liver and other diseases. CSL will fund a Phase 2 RENAL trial, a planned Phase 3 trial and additional Phase 2 studies.

Reuters reported on October 5, 2026, that the agreement could reach USD 1.6 billion before development funding. Commercial profits are planned to be split 55 percent for CSL and 45 percent for Alentis.

Fiscal results set the baseline

Simply Wall St reported that CSL generated USD 15.8 billion in revenue in fiscal 2026, up 1.50 percent from fiscal 2025. The same fiscal-year review cited a USD 2.58 billion net loss, compared with profit of USD 3.00 billion in fiscal 2025.

The figures explain why the Alentis agreement matters beyond its headline value: it adds a development program to CSL's nephrology strategy while requiring funding for several clinical studies. The partnership's 55 percent profit share gives CSL the larger commercial interest if lixudebart reaches the market.

Three dated CSL milestones

On September 16, 2026, TipRanks reported that CSL set its annual meeting for October 27, 2026, at 10:00 a.m. AEDT. On August 18, 2026, CSL presented fiscal 2026 results for the year ended June 30, 2026, including USD 15.8 billion in revenue. On October 5, 2026, CSL announced the USD 355 million lixudebart payment and the USD 1.2 billion milestone framework.

What comes next for CSL?

CSL lists its 2026 annual general meeting for October 27, 2026. Simply Wall St lists February 10, 2027, for CSL's first-half fiscal 2027 results.

CSL stock and market value

CSL stock was trading at EUR 114.58 at Lang & Schwarz on October 12, 2026, at 9:09 a.m. CEST. The finance quote placed CSL's market capitalization at AUD 88.5 billion on October 12, 2026, while a market profile identifies CSL.AX as the ASX listing in the healthcare sector.

The further course of trading is shown by the continuously updated real-time quote of CSL stock.